Future Of GLP-1s: Iconovo Starts Development Of Intranasal Semaglutide
Eventually, The Firm Will Look For A Clinical Development Partner
Executive Summary
With asthma inhalers already in development, Iconovo has turned to a more innovative approach and looks at transforming injectable semaglutide into an intranasal drug.